| Autor: |
Janni Christensen, Wai-Hong Tham, David B. Olsen, Alan F. Cowman, Anthony N. Hodder, Brodie L Bailey, Peter E. Czabotar, Brad E. Sleebs, Zhuyan Guo, Tony Triglia, Stephen Scally, Nicholas Murgolo, John A. Mccauley, Anna Ngo, Richard W Birkinshaw, Paola Favuzza, Kym N Lowes, Melanie H. Dietrich, Manuel de Lera Ruiz |
| Rok vydání: |
2021 |
| Předmět: |
|
| Popis: |
Plasmepsin IX (PMIX) and X (PMX) are aspartyl proteases of Plasmodium spp. that play essential roles in parasite egress, invasion and development. Consequently, they are important drug targets for Plasmodium falciparum and P. vivax. WM4 and WM382 are potent inhibitors of PMIX and PMX that block invasion of liver and blood stages and transmission to mosquitoes. WM4 specifically inhibits PMX whilst WM382 is a dual inhibitor of PMIX and PMX. To understand the function of PMIX and PMX proteases we identified new protein substrates in P. falciparum and together with detailed kinetic analyses and structural analyses identified key molecular interactions in the active site responsible for the specificity of WM4 and WM382 inhibition. The crystal structures of PMX apo enzyme and the protease/drug complexes of PMX/WM382 and PMX/WM4 for P. falciparum and P. vivax have been solved. We show PMIX and PMX have similar substrate selectivity, however, there are distinct differences for both peptide and full-length protein substrates through differences in localised 3-dimensional structures for the enzyme substrate-binding cleft and substrate interface. The differences in affinities of WM4 and WM382 binding for PMIX and PMX map to variations in surface interactions with each protease in the S' region of the active sites. Crystal structures of PMX reveal interactions and mechanistic detail on the selectivity of drug binding which will be important for further development of clinical candidates against these important molecular targets. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
